Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Distinct expression of Tim-3 during different stages of rat experimental autoimmune neuritis.

Authors: Zhang, ZY  Schluesener, HJ  Zhang, Z 
Citation: Zhang ZY, etal., Brain Res Bull. 2011 Oct 10;86(3-4):229-34. doi: 10.1016/j.brainresbull.2011.07.005. Epub 2011 Jul 18.
Pubmed: (View Article at PubMed) PMID:21784136
DOI: Full-text: DOI:10.1016/j.brainresbull.2011.07.005

Experimental autoimmune neuritis (EAN) is a well-known animal model of human demyelinating polyneuropathies and is characterized by inflammation and demyelination in the peripheral nervous system. Tim-3 had been identified as a Th1-specific marker negatively regulating autoimmunity or inflammatory diseases. Here we have studied by immunohistochemistry the spatiotemporal accumulation of Tim-3(+) cells in sciatic nerves of EAN rats, particularly focusing on its association with alternatively activated macrophages. Our results showed that time course of Tim-3(+) cell accumulation correlated positively with disease progression of EAN; but distinct major cellular resources of Tim-3 were observed at different disease stages of EAN: during the early phase of EAN, the main cellular resource were T cells, but at the peak and during recovery phase of EAN, Tim-3 was mostly expressed on CD68(+) macrophages or CD163(+) cells. Further investigation suggested that accumulation of CD163(+) cells, particularly their relative abundances to activated macrophages at different time points, were in accordance with the recovery from EAN. Therefore, Tim3(+) cells might include a distinct macrophage population, which may be involved in anti-inflammatory effect and recovery from EAN.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 9686114
Created: 2015-02-02
Species: All species
Last Modified: 2015-02-02
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.